糖尿病和糖尿病肾病患者血清中糖基化终产物的检测

目的 :研究糖基化终产物 ( AGEs)与糖尿病及糖尿病肾病的关系。方法 :用竞争性酶联免疫吸附测定 ( ELISA)法测定糖尿病 ( DM)、糖尿病肾病 ( DN)和 DN并发慢性肾功能不全 ( CRF)患者治疗前后血清 AGEs水平 ,以正常人血清作对照。结果 :DM患者血清 AGEs水平 ( 2 1 .3±6.0 ) mg· L-1 ]明显高于正常人 ( 1 0 .6± 3.1 ) mg· L-1 ]( P<0 .0 1 ) ;DN患者血清 AGEs水平( 33.1± 9.3) mg·L-1 ]明显高于 DM( P<0 .0 1 ) ;DN并发 CRF患者血液透析治疗后血清 AGEs水平 ( 2 1 .7± 9.8) mg· L-1 ]低于治疗前 ( 36.3± 1 4 .1 ) mg· L-1 ]( P<0 .0 5 )。结论 :竞争性ELISA法可用来监测 DM和 DN的进展及评价疗效

Determination of Serum Advanced Glycation End Products in Patients with Diabetes Mellitus and Diabetic Nephropathy by ELISA

Objective: To investigate the relationship between advanced glycation end products (AGEs) and diabetes mellitus (DM) as well as diabetic nephropathy (DN), the serum AGEs levels in patients with DM and DN were determined. Methods: The serum AGEs level was measured using competitive ELISA in patients with DM, DN, and DN with chronic renal failure (CRF) before and after hemodialysis, the serum AGEs level in normal subjects as control. Results: The serum AGEs level in patients with DM (21.3± 6.0)mg·L -1 ] was markedly higher than that in normal subjects (10.6±3.1)mg·L -1 ] and the serum AGEs level in patients with DN (33.1±9.3)mg·L -1 ] was significantly increased ( P <0.01). The serum AGEs level in DN with CRF after hemodialysis (21.7±9.8 mg·L -1 ) was reduced as compared with before hemodialysis (36.3±14.1)mg·L -1 , P <0.05]. Conclusion: The determination technique of the serum AGEs using competitive ELISA can be used to monitor the progressions of DM, DN ,and their therapeutic efficacy.